Salīdzināt metodes

	Izobologrammas analīze	Čou-Talalaja metode	Populācijas farmakodinamiskā modelēšana	Analīze pēc Šilda (Schild Analysis)
Nozare	Farmakoloģija	Farmakoloģija	Farmakoloģija	Farmakoloģija
Saime	Process / pipeline	Process / pipeline	Process / pipeline	Process / pipeline
Izcelsmes gads	1926	1983	1992	1947
Autors	Salvatore Loewe	Ting-Chao Chou and Paul Talalay	Lewis Sheiner and Stephen Roush	Henry Schild
Tips	synergy quantification	synergy quantification	dose-response modeling	antagonism quantification
Pirmavots	Loewe, S. (1926). Die Mischtoxizität. Zeitschrift für Experimentelle Pathologie und Therapie, 24, 315-334.	Chou, T. C., & Talalay, P. (1983). Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Advances in Enzyme Regulation, 22, 27-55.	Dahlström, B., & Nyberg, L. (1993). Population pharmacokinetics and pharmacodynamics. Clinical Pharmacokinetics, 24(1), 45-57.	Schild, H. O. (1947). pA, a new scale for the measurement of drug antagonism. Journal of Physiology, 106(3), 337-357.
Citi nosaukumi	isobol, combination index, synergy testing	CI method, Chou method, median-effect analysis	PopPD, population PD, hierarchical PD modeling	Schild plot, pA2
Saistītās	3	3	3	3
Kopsavilkums	Isobologram analysis is a graphical and quantitative method for detecting and classifying drug interactions, developed by Salvatore Loewe in 1926. It uses dose-response data from two drugs applied individually and in combination to determine whether their interaction is additive, synergistic, or antagonistic.	The Chou-Talalay method is a quantitative framework for analyzing drug interactions, developed by Ting-Chao Chou and Paul Talalay in 1983. It combines median-effect principle with the combination index (CI) to provide rigorous, model-independent assessment of synergistic, additive, or antagonistic drug effects.	Population pharmacodynamic (PopPD) modeling integrates pharmacokinetics with individual dose-response relationships across patient populations to characterize drug efficacy and tolerability. Pioneered by Lewis Sheiner and colleagues, PopPD accounts for inter-individual variability in drug effects and enables rational dose optimization and response prediction.	Schild analysis is a quantitative method for characterizing competitive receptor antagonism developed by Henry Schild in 1947. It uses dose-response curves in the presence and absence of antagonist to estimate the antagonist affinity constant (pA2), enabling standardized comparison of antagonist potency across drugs and experimental systems.